摘要
临床上有20%～25%的非小细胞肺癌(NSCLC)患者可手术治疗,但5年生存率也只有40%左右。辅助化疗是部分早期可切除肺癌的标准治疗方式,可使4%～15%的患者生存获益。但是,ⅠB期NSCLC是否能从辅助化疗中获益仍存在争议。近年来,多个临床研究评价了ⅠB期NSCLC辅助化疗的疗效,我们通过分析这些临床研究,寻找ⅠB期NSCLC的高危人群和辅助化疗的适应证。
Although surgery is regarded as the best possible treatment for patients with early stage non-small cell lung cancer （ NSCLC ）, only 20% -25% of patients have resectable disease at presentation. Despite optimal surgical treatment, 5-year survival rates in patients with resectable NSCLC are historically modest（40% ）. Adjuvant chemotherapy has been a standard treatment after complete resection in early stage NSCLC,and 4%-15% patients can benefit from it. In recent years, although multiple randomized trials assess- ing the efficacy of adjuvant chemotherapy for stage I B NSCLC have been reported, the benefit of adjuvant chemotherapy in patients with stage I B NSCLC is controversial. Herein, we review the results of the major adjuvant chemotherapy trials and find the high-risk patients and their implications for the treatment of stage I B NSCLC.
出处
《临床肿瘤学杂志》
CAS
2012年第9期856-859,共4页
Chinese Clinical Oncology
基金
首都医学发展基金资助项目(2007-3042)
关键词
非小细胞肺癌
ⅠB期
辅助化疗
Non-small cell lung cancer
Stage I B
Adjuvant chemotherapy
